Rigel Pharmaceuticals (RIGL) Share-based Compensation (2010 - 2026)

Rigel Pharmaceuticals has reported Share-based Compensation for 17 years, with the latest figure at $3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 3.97% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $12.8 million (up 21.36% YoY), and the FY2025 full-year result was $12.7 million, up 2.57% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.5 million, up from $2.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $5.1 million in Q1 2024, with the low at $1.9 million in Q4 2023.
• Average Share-based Compensation over 5 years is $2.9 million, with a median of $2.7 million recorded in 2025.
• Year-over-year, Share-based Compensation sank 52.62% in 2023 and soared 86.15% in 2024.
• Tracing RIGL's Share-based Compensation over 5 years: stood at $4.1 million in 2022, then slumped by 52.62% to $1.9 million in 2023, then rose by 7.97% to $2.1 million in 2024, then jumped by 31.67% to $2.7 million in 2025, then advanced by 25.76% to $3.5 million in 2026.
• The last three Share-based Compensation figures came in at $3.5 million (Q1 2026), $2.7 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.

Peer Comparison